BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28151757)

  • 1. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?
    Ribero S; Stucci LS; Daniels GA; Borradori L
    Curr Opin Oncol; 2017 Mar; 29(2):129-135. PubMed ID: 28151757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma.
    Mavropoulos JC; Aldabagh B; Arron ST
    Semin Cutan Med Surg; 2014 Jun; 33(2):72-5. PubMed ID: 25085665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
    Harwood CA; Proby CM; Inman GJ; Leigh IM
    Acta Derm Venereol; 2016 Jan; 96(1):3-16. PubMed ID: 26084328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for advanced cutaneous squamous cell carcinoma.
    Fitzgerald K; Tsai KK
    Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for cutaneous oncology: a review of novel treatment options for non-melanoma skin cancer: part II.
    Walls B; Jordan L; Diaz L; Miller R
    J Drugs Dermatol; 2014 Aug; 13(8):955-8. PubMed ID: 25116974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?
    Soura E; Gagari E; Stratigos A
    Curr Opin Oncol; 2019 Sep; 31(5):461-468. PubMed ID: 31394558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
    Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma.
    Petzold A; Steeb T; Wessely A; Schatton T; Berking C; Heppt MV
    Eur J Cancer; 2022 Jul; 170():42-53. PubMed ID: 35594611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma.
    McMullen CP; Ow TJ
    Otolaryngol Clin North Am; 2021 Apr; 54(2):343-355. PubMed ID: 33583597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
    Dereure O; Missan H; Girard C; Costes V; Guillot B
    Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany.
    Kramb F; Doerfer C; Meiwes A; Ramakrishnan K; Eigentler T; Garbe C; Keim U; Leiter U
    Acta Derm Venereol; 2022 Jan; 102():adv00637. PubMed ID: 34842930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of the existing evidence.
    Steeb T; Wessely A; Heppt F; Harlaß M; Berking C; Heppt MV
    Br J Dermatol; 2020 Aug; 183(2):380-382. PubMed ID: 32068244
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.
    Pezeshki S; Hemmati S; Rezaei N
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):819-822. PubMed ID: 32852235
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular and immune targets in cutaneous squamous cell carcinoma.
    Galambus J; Tsai KY
    Mol Carcinog; 2023 Jan; 62(1):38-51. PubMed ID: 36000298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma.
    Petersen ET; Ahmed SR; Chen L; Silapunt S; Migden MR
    Future Oncol; 2019 Sep; 15(27):3171-3184. PubMed ID: 31382778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the Use and Treatment of Targeted Molecular Inhibitors for Locally Advanced and Metastatic Non-Melanoma Skin Cancers.
    Odueyungbo M; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S49-56. PubMed ID: 26730974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
    Rudnick EW; Thareja S; Cherpelis B
    Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.